Market News & Trends
Ligand Subsidiary Pelthos Therapeutics to Combine With Channel Therapeutics
Ligand Pharmaceuticals Incorporated and Channel Therapeutics Corporation recently announced the signing of a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc.…
eschbach Introduces SAMI: The Next Evolution in AI-Empowered Process Manufacturing
Global software developer eschbach, the provider of the Shiftconnector enterprise manufacturing platform for process manufacturing, is proud to unveil a powerful new chat feature within…
Lonza Joins Centre for Continuous Manufacturing & Advanced Crystallisation to Enhance Service Offering
Lonza, a global development and manufacturing partner to the pharmaceutical and biotech markets, recently announced it has joined CMAC, a world leading centre for medicines…
Cullinan Therapeutics Receives Approval From EMA to Initiate Phase 1 Trial of a Bispecific CD19 T Cell Engager Administered Subcutaneously in Patients With RA
Cullinan Therapeutics, Inc. recently announced the European Medicines Agency (EMA) approved the company’s Clinical Trial Application (CTA) for CLN-978. The Phase 1 clinical trial will…
AccuStem Sciences Signs Agreement to Access Blood Samples From Lung Cancer Screening Trial to Expedite MSC Commercialization Plan
AccuStem Sciences, Inc.recently announced a development agreement to access blood samples from the multi-institutional, prospective, randomized Rete Italiana di Screening Polmonare (RISP) clinical trial. This…
Q32 Bio Doses First Patients in Both Part A Open-Label Extension & Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
Q32 Bio Inc. recently announced it has dosed the first patients in both the Part A open-label extension (OLE) and Part B of the SIGNAL-AA…
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
Decoy Therapeutics, Inc. recently announced Massachusetts Institute of Technology (MIT) Professor and Moderna Co-founder Robert S. Langer, ScD will join the company’s Scientific Advisory Board…
Addgene Adds Science & Tech Leaders to its Management Team & Board of Directors
Addgene recently announced the expansion of its management team and Board of Directors with numerous industry leaders. These key appointments support Addgene’s growth strategy and illustrate…
Conduit Pharmaceuticals Announces Leadership Changes
Conduit Pharmaceuticals Inc. recently announced key leadership changes to support the company’s next phase of growth and execution. Dr. Andrew Regan, the founder and initial…
Researchers Recruit Killers to a Tumor Fight: Antibody Immunotherapies Developed to Treat Glioblastoma
Purdue University researchers are developing innovative antibody-based immunotherapies that recruit and improve the function of the body’s innate immune system to treat glioblastoma, an incurable…
Agno Pharma’s Particle Sciences, Inc. Achieves ISO 13485:2016 Certification
Agno Pharma recently announced its subsidiary, Particle Sciences, Inc., has earned ISO 13485:2016 certification from National Quality Assurance, U.S.A. (NQA). This achievement underscores Particle Sciences’…
Source BioScience Acquires Cambridge Clinical Laboratories
Source BioScience UK Ltd, an industry-leading provider of genomic services and histopathology diagnostics, announced it had completed the acquisition of Cambridge Clinical Laboratories (CCL), a…
Oculis Completes Enrollment in Both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
Oculis Holding AG recently announced it has completed enrollment in both Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in DME, designed as…
Imbria Pharmaceuticals Raises $57.5M Financing; Appoints Alvin Shih, MD, as CEO
Imbria Pharmaceuticals, Inc. recently announced the successful closing of a $57.5 million Series B financing with a top-tier syndicate of life science investors led by…
Solu Therapeutics Closes $41M Financing & Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients With CMML & Other Advanced Hematologic Malignancies
Solu Therapeutics recently announced the successful completion of a $41 million Series A financing that included participation from five new investors – Eli Lilly and…
CERo Therapeutics Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
CERo Therapeutics Holdings, Inc. recently announced its first clinical trial site for the its Phase 1 clinical trial of CER-1236. The trial is focused on…
Microbot Medical Shares Results From Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY Endovascular Robotic System
Microbot Medical Inc. presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting. The study…
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
Palisade Bio, Inc. recently announced the completion of enrollment and dosing in all five Phase 1a SAD cohorts, all four MAD cohorts, and the food…
Tolebrutinib Phase 3 Data Demonstrates Benefit on Disability Progression in Multiple Sclerosis
The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with…
Upperton Continues Strategic Growth With the Appointment of Michael Mellor-Clark as Chief Commercial Officer
Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), continues its growth following the build of a new sterile manufacturing facility with…
